DexCom PT Raised to $44.00 at Benchmark Co. (DXCM)
Equities research analysts at Benchmark Co. lifted their price objective on shares of DexCom (NASDAQ:DXCM) from $40.00 to $44.00 in a research note issued to investors on Tuesday, StockRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. Benchmark Co.’s target price suggests a potential upside of 19.18% from the company’s current price.
DXCM has been the subject of a number of other recent research reports. Analysts at Raymond James reiterated a “buy” rating on shares of DexCom in a research note to investors on Thursday, November 7th. They now have a $34.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “buy” rating on shares of DexCom in a research note to investors on Thursday, November 7th. They now have a $32.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of DexCom from $27.00 to $40.00 in a research note to investors on Thursday, November 7th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $30.30.
DexCom (NASDAQ:DXCM) traded down 0.89% on Tuesday, hitting $36.92. The stock had a trading volume of 1,020,504 shares. DexCom has a 52 week low of $14.05 and a 52 week high of $38.13. The stock’s 50-day moving average is $34.65 and its 200-day moving average is $28.98. The company’s market cap is $2.650 billion.
DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, November 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.04. The company had revenue of $42.90 million for the quarter, compared to the consensus estimate of $35.90 million. During the same quarter in the prior year, the company posted ($0.25) earnings per share. The company’s quarterly revenue was up 85.7% on a year-over-year basis. Analysts expect that DexCom will post $-0.47 EPS for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.